Compare · ABBV vs PCVX
ABBV vs PCVX
Side-by-side comparison of AbbVie Inc. (ABBV) and Vaxcyte Inc. (PCVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PCVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 55.4x PCVX ($8.12B).
- Over the past year, ABBV is up 34.5% and PCVX is up 55.2% - PCVX leads by 20.7 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 12 for PCVX).
- ABBV has more recent analyst coverage (25 ratings vs 11 for PCVX).
- Company
- AbbVie Inc.
- Vaxcyte Inc.
- Price
- $254.52+0.06%
- $56.23+0.46%
- Market cap
- $449.63B
- $8.12B
- 1M return
- +14.38%
- +14.11%
- 1Y return
- +34.48%
- +55.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2020
- News (4w)
- 23
- 12
- Recent ratings
- 25
- 11
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Vaxcyte Inc.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest PCVX
- SEC Form 4 filed by Director Markels John
- New insider Markels John claimed no ownership of stock in the company (SEC Form 3)
- Vaxcyte Inc. filed SEC Form 8-K: Leadership Update
- Vaxcyte to Participate in Upcoming Investor Conferences
- PRESIDENT AND CFO Guggenhime Andrew exercised 10,000 shares at a strike of $5.35 and sold $572,837 worth of shares (10,000 units at $57.28) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF OPERATING OFFICER Wassil Jim exercised 516 shares at a strike of $5.35 and sold $126,736 worth of shares (2,250 units at $56.33) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 156,760 units (SEC Form 4)
- SEC Form 144 filed by Vaxcyte Inc.
- CHIEF EXECUTIVE OFFICER Pickering Grant sold $1,338,270 worth of shares (24,237 units at $55.22) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 452,466 units (SEC Form 4)
- SEC Form 144 filed by Vaxcyte Inc.
- SEC Form 4 filed by Director Slaoui Moncef